JP6758832B2 - 抗ｇｄｆ１５抗体 - Google Patents

抗ｇｄｆ１５抗体 Download PDF

Info

Publication number
JP6758832B2
JP6758832B2 JP2015549810A JP2015549810A JP6758832B2 JP 6758832 B2 JP6758832 B2 JP 6758832B2 JP 2015549810 A JP2015549810 A JP 2015549810A JP 2015549810 A JP2015549810 A JP 2015549810A JP 6758832 B2 JP6758832 B2 JP 6758832B2
Authority
JP
Japan
Prior art keywords
seq
acid sequence
amino acid
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015549810A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016508984A (ja
JP2016508984A5 (OSRAM
Inventor
ロレンナ ラーナー，
ロレンナ ラーナー，
サンドラ アボット，
サンドラ アボット，
アイリン バイ，
アイリン バイ，
ティン チェン，
ティン チェン，
マリア イザベル チウ，
マリア イザベル チウ，
チン リウ，
チン リウ，
ローラ ポリング，
ローラ ポリング，
ニアンジュン タオ，
ニアンジュン タオ，
ソリー ウェイラー，
ソリー ウェイラー，
ジーガン ウェン，
ジーガン ウェン，
ウィリアム エム． ジュニア ウィンストン，
ウィリアム エム． ジュニア ウィンストン，
ジェノ ギュリス，
ジェノ ギュリス，
Original Assignee
アベオ ファーマシューティカルズ， インコーポレイテッド
アベオ ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アベオ ファーマシューティカルズ， インコーポレイテッド, アベオ ファーマシューティカルズ， インコーポレイテッド filed Critical アベオ ファーマシューティカルズ， インコーポレイテッド
Publication of JP2016508984A publication Critical patent/JP2016508984A/ja
Publication of JP2016508984A5 publication Critical patent/JP2016508984A5/ja
Application granted granted Critical
Publication of JP6758832B2 publication Critical patent/JP6758832B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015549810A 2012-12-21 2013-12-20 抗ｇｄｆ１５抗体 Active JP6758832B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261745508P 2012-12-21 2012-12-21
US61/745,508 2012-12-21
US201361827325P 2013-05-24 2013-05-24
US61/827,325 2013-05-24
PCT/US2013/077139 WO2014100689A1 (en) 2012-12-21 2013-12-20 Anti-gdf15 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019007928A Division JP2019056018A (ja) 2012-12-21 2019-01-21 抗ｇｄｆ１５抗体

Publications (3)

Publication Number Publication Date
JP2016508984A JP2016508984A (ja) 2016-03-24
JP2016508984A5 JP2016508984A5 (OSRAM) 2017-02-09
JP6758832B2 true JP6758832B2 (ja) 2020-09-30

Family

ID=50069279

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015549810A Active JP6758832B2 (ja) 2012-12-21 2013-12-20 抗ｇｄｆ１５抗体
JP2019007928A Withdrawn JP2019056018A (ja) 2012-12-21 2019-01-21 抗ｇｄｆ１５抗体
JP2021009528A Withdrawn JP2021061864A (ja) 2012-12-21 2021-01-25 抗ｇｄｆ１５抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019007928A Withdrawn JP2019056018A (ja) 2012-12-21 2019-01-21 抗ｇｄｆ１５抗体
JP2021009528A Withdrawn JP2021061864A (ja) 2012-12-21 2021-01-25 抗ｇｄｆ１５抗体

Country Status (13)

Country Link
US (6) US9175076B2 (OSRAM)
EP (2) EP2934584B1 (OSRAM)
JP (3) JP6758832B2 (OSRAM)
KR (1) KR102208861B1 (OSRAM)
CN (1) CN105073133B (OSRAM)
AR (1) AR094271A1 (OSRAM)
AU (1) AU2013364133B2 (OSRAM)
CA (1) CA2896076C (OSRAM)
DK (1) DK2934584T3 (OSRAM)
EA (1) EA038645B1 (OSRAM)
ES (1) ES2791183T3 (OSRAM)
MX (1) MX370720B (OSRAM)
WO (1) WO2014100689A1 (OSRAM)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2006381B1 (en) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
CA2700701C (en) 2007-09-26 2020-12-29 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
NZ717429A (en) 2008-04-11 2018-07-27 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CN108715614A (zh) 2010-11-30 2018-10-30 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
EP2694092B1 (en) 2011-04-08 2017-01-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
BR112014018575A2 (pt) 2012-01-26 2017-07-04 Amgen Inc polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
WO2013148117A1 (en) 2012-03-27 2013-10-03 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
EP3721900A1 (en) 2012-08-24 2020-10-14 Chugai Seiyaku Kabushiki Kaisha Fcgammariib-specific fc region variant
AU2013322628B2 (en) 2012-09-26 2017-03-02 Julius-Maximilians-Universitat Wurzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15)
CN105073133B (zh) 2012-12-21 2021-04-20 Aveo制药公司 抗gdf15抗体
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
WO2014120619A2 (en) 2013-01-30 2014-08-07 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
KR102318483B1 (ko) 2013-04-02 2021-10-27 추가이 세이야쿠 가부시키가이샤 Ｆｃ영역 개변체
WO2015017710A1 (en) 2013-07-31 2015-02-05 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs
WO2015066259A1 (en) * 2013-10-31 2015-05-07 Regeneron Pharmaceuticals, Inc. Competitive ligand binding assay for detecting neutralizing antibodies
CN120919282A (zh) 2013-11-21 2025-11-11 布里格姆及妇女医院股份有限公司 用于治疗肺高压的组合物和方法
TWI681972B (zh) 2014-03-19 2020-01-11 財團法人臺灣基督長老教會馬偕紀念社會事業基金會馬偕紀念醫院 抗免疫原性醣肽之抗體，包含彼等之組合物及其用途
GB2524553C (en) * 2014-03-26 2017-07-19 Julius-Maximilians-Universitãt Würzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
GB2524552B (en) * 2014-03-26 2017-07-12 Julius-Maximilians-Universitãt Wurzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer
DK3122775T3 (da) 2014-03-26 2020-02-03 Univ Wuerzburg J Maximilians Monoklonale antistoffer til vækst- og differentieringsfaktor 15 (gdf-15), og anvendelser deraf til behandling af cancer kakeksi og cancer
EA201790051A1 (ru) 2014-06-20 2017-04-28 Авео Фармасьютикалз, Инк. Лечение хронического заболевания почек и другого нарушения функции почек при помощи модулятора gdf15
JP6910800B2 (ja) * 2014-06-20 2021-07-28 アベオ ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ１５調節剤を用いたうっ血性心不全及びその他の心機能不全の治療
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
ES2883158T3 (es) 2014-07-30 2021-12-07 Ngm Biopharmaceuticals Inc Composiciones y procedimientos de uso para el tratamiento de trastornos metabólicos
WO2016019368A1 (en) 2014-08-01 2016-02-04 The Brigham And Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
EP3851122A1 (en) 2014-09-25 2021-07-21 Aveo Pharmaceuticals Inc. Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
EP3201229B1 (en) * 2014-09-30 2020-09-09 Vib Vzw A method of treating joint disease
JP6663428B2 (ja) 2014-10-30 2020-03-11 アクセルロン ファーマ， インコーポレイテッド Ｇｄｆ１５ポリペプチドを使用する、赤血球を増加させるための方法および組成物
AP2017009828A0 (en) 2014-10-31 2017-03-31 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
KR102650420B1 (ko) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
PT3286223T (pt) * 2015-04-23 2024-03-22 HaemaLogiX Ltd Recetores de antigénio quimérico do antigénio do mieloma kappa e suas utilizações
CN106349388B (zh) * 2015-07-17 2021-04-02 上海佳文英莉生物技术有限公司 一种促细胞程序性坏死抗体及其应用
GB201512733D0 (en) * 2015-07-20 2015-08-26 Genagon Therapeutics Ab Therapeutic agents for treating conditions associated with elevated GDF15
DK3356827T3 (da) 2015-10-02 2024-01-08 Univ Wuerzburg J Maximilians Gdf-15 som en diagnostisk markør til forudsigelse af det kliniske resultat af en behandling med immun-checkpoint-blokkere
PT3355919T (pt) * 2015-10-02 2023-01-06 Univ Wuerzburg J Maximilians Terapia de combinação utilizando inibidores do fator de crescimento e diferenciação 15 (gdf-15) humano e bloqueadores de pontos de controlo imunitários
RU2018119317A (ru) * 2015-10-28 2019-12-04 Йейл Юниверсити Гуманизированное антитело к dkk2 и его применение
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
CA3013443C (en) * 2016-02-01 2021-06-15 Eli Lilly And Company Parathyroid hormone - anti-rankl antibody fusion compounds
WO2017147742A1 (en) * 2016-02-29 2017-09-08 Eli Lilly And Company Gfral receptor therapies
AU2017228489A1 (en) * 2016-03-04 2018-09-06 Ngm Biopharmaceuticals, Inc. Compositions and methods for modulating body weight
TWI897070B (zh) * 2016-03-31 2025-09-11 美商恩格姆生物製藥公司 結合蛋白質及其使用方法
US11312766B2 (en) 2016-04-27 2022-04-26 Novartis Ag Antibodies against growth differentiation factor 15 and uses thereof
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
NL2017267B1 (en) * 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
KR20190035863A (ko) * 2016-08-05 2019-04-03 알라코스 인크. 암 치료를 위한 항Siglec-7 항체
TW202300168A (zh) 2016-08-05 2023-01-01 日商中外製藥股份有限公司 Il-8相關疾病之治療用或預防用組成物
CN110072541B (zh) * 2016-12-06 2023-05-02 圣文森特医院悉尼有限公司 肥胖和饮食失调的治疗
GB201700567D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
CA3070100A1 (en) 2017-07-17 2019-01-24 Janssen Biotech, Inc. Antigen binding regions against fibronectin type iii domains and methods of using the same
AU2019208025A1 (en) * 2018-01-11 2020-09-03 Allakos, Inc. Anti-Siglec-7 antibodies having reduced effector function
TWI724392B (zh) * 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
AU2019253462B2 (en) 2018-04-09 2025-04-24 Amgen Inc. Growth differentiation factor 15 fusion proteins
WO2020033797A1 (en) * 2018-08-09 2020-02-13 The Wistar Institute Anti-follicule stimulating hormone receptor antibodies
EP3841121A2 (en) * 2018-08-20 2021-06-30 Pfizer Inc. Anti-gdf15 antibodies, compositions and methods of use
KR102238927B1 (ko) * 2018-08-30 2021-04-12 서울대학교산학협력단 세포 내에서 nag-1 단백질의 이동을 조절하는 펩티드 및 이의 용도
WO2020053147A1 (en) * 2018-09-10 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of an inhibitor of ntsr1 activation or expression for preventing weight loss, muscle loss, and protein blood level decrease in subjects in need thereof
CR20210193A (es) 2018-10-22 2021-06-15 Janssen Pharmaceutica Nv Proteínas de fusión de péptido similar al glucagón 1 (glp1)-factor de diferenciación de crecimiento 15 (gdf15) y usos de estas
WO2021066751A1 (en) * 2019-10-02 2021-04-08 Aslan Pharmaceuticals Pte. Ltd. Antigen specific binding domains and antibody molecules
WO2021111636A1 (ja) * 2019-12-06 2021-06-10 大塚製薬株式会社 抗ｇｄｆ１５抗体
CN111393526B (zh) * 2020-03-30 2022-04-12 中国人民解放军第四军医大学 抗gdf15中和性单克隆抗体及其应用
JP7495529B2 (ja) 2020-06-04 2024-06-04 テグ キョンプク インスティテュート オブ サイエンス アンド テクノロジー Ｇｆｒａｌ拮抗抗体及びその用途
KR20230095097A (ko) * 2020-10-30 2023-06-28 히데아키 하라 눈 조직 섬유화의 저해에 사용하기 위한 gdf15 조절 물질
KR20230107309A (ko) 2020-11-10 2023-07-14 카탈임 게엠베하 항-gdf15 항체 및 암 치료용 투여 용법
AR125037A1 (es) * 2021-03-08 2023-05-31 Medimmune Llc Anticuerpos dirigidos contra gdf-15
AU2022251923A1 (en) 2021-03-31 2023-11-16 Cambridge Enterprise Limited Therapeutic inhibitors of gdf15 signalling
US20250019427A1 (en) 2021-08-10 2025-01-16 Byomass Inc. Anti-gdf15 antibodies, compositions and uses thereof
WO2023079430A1 (en) 2021-11-02 2023-05-11 Pfizer Inc. Methods of treating mitochondrial myopathies using anti-gdf15 antibodies
US20250382359A1 (en) 2021-12-22 2025-12-18 Byomass Inc. Targeting gdf15-gfral pathway
JP7762311B2 (ja) * 2022-01-26 2025-10-29 ユンナン バイヤオ グループ カンパニー リミテッド 抗成長分化因子１５の抗体分子及びその応用
WO2023217068A1 (zh) 2022-05-09 2023-11-16 舒泰神（北京）生物制药股份有限公司 特异性识别gdf15的抗体及其应用
CN116041497A (zh) * 2022-12-22 2023-05-02 杭州贤至生物科技有限公司 一种猫杯状病毒（fcv）重组蛋白单克隆抗体及制备方法
CN116444667B (zh) * 2023-06-13 2023-09-01 上海驯鹿生物技术有限公司 一种靶向gdf15的全人源抗体及其应用
WO2025072516A1 (en) * 2023-09-27 2025-04-03 Aveo Pharmaceuticals, Inc. Methods of reducing weight loss using anti-gdf15 antibodies
WO2025146488A1 (en) 2024-01-05 2025-07-10 Catalym Gmbh Anti-hgdf-15 antibody for use in the treatment of cancer in a patient in combination with a cancer antigen-targeted drug conjugate that induces cancer cell stress

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US6180602B1 (en) 1992-08-04 2001-01-30 Sagami Chemical Research Center Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent
WO1994003599A1 (fr) 1992-08-04 1994-02-17 Sagami Chemical Research Center ADNc HUMAIN ET PROTEINE POUR LAQUELLE CODE CET ADNc
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US6521227B1 (en) 1999-11-18 2003-02-18 Peter L. Hudson Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
US5994102A (en) 1994-12-15 1999-11-30 Human Genome Sciences, Inc. Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
WO1996018730A1 (en) 1994-12-15 1996-06-20 Human Genome Sciences, Inc. Prostatic growth factor
ATE423788T1 (de) 1995-06-22 2009-03-15 St Vincents Hosp Sydney Neues tgf-beta-ahnliches cytokin
WO1999006445A1 (en) 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-15
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
EP2128260A3 (en) 1998-10-07 2010-06-16 STRYKER CORPORATION (a Michigan corporation) Modified TGF-beta superfamily proteins
US6465181B2 (en) 1999-03-25 2002-10-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
ES2275513T3 (es) 1999-05-17 2007-06-16 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh Propiedades neuroprotectoras de gdf-15, un miembro de la superfamilia de tgf-beta.
AU2001250182B2 (en) 2000-04-20 2006-06-08 St Vincent's Hospital Sydney Limited Diagnostic assay and method of treatment involving macrophage inhibitory cytokine -1 (mic-1)
WO2002020759A2 (en) 2000-09-08 2002-03-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US7157235B2 (en) 2002-06-17 2007-01-02 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
US7919084B2 (en) 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
JP2006515747A (ja) 2002-11-01 2006-06-08 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
EP1575512A4 (en) 2002-11-08 2007-08-29 Barnes Jewish Hospital METHOD AND COMPOSITIONS FOR THE EPITHELIAL CELL DIFFERENTIATION IN THE PROSTATE
US20060188889A1 (en) 2003-11-04 2006-08-24 Christopher Burgess Use of differentially expressed nucleic acid sequences as biomarkers for cancer
WO2005036608A2 (en) 2003-10-10 2005-04-21 That Corporation Low-power integrated-circuit signal processor with wide dynamic range
US7981598B2 (en) 2004-03-26 2011-07-19 Takeda Pharmaceutical Company Limited Preventive/remedy for respiratory diseases
US8192735B2 (en) * 2004-04-13 2012-06-05 St Vincent's Hospital Sydney Limited Method for modulating appetite
CA2534871C (en) 2006-02-15 2015-08-04 The Ohio State University Research Foundation Three-gene test to differentiate malignant from benign thyroid nodules
US20070237713A1 (en) 2006-04-04 2007-10-11 Fan Rong A PCan065 Antibody Compositions and Methods of Use
CN106018820B (zh) 2006-08-04 2018-04-27 汉诺威医学院 根据gdf-15评价心脏介入风险的工具与方法
EP1884777A1 (en) 2006-08-04 2008-02-06 Medizinische Hochschule Hannover Means and methods for assessing the risk of cardiac interventions based on GDF-15
CN101854947A (zh) * 2007-08-16 2010-10-06 圣文森特医院悉尼有限公司 用于调节巨噬细胞抑制因子(mic-1)活性的药剂和方法
WO2009046495A1 (en) 2007-10-09 2009-04-16 St Vincent's Hospital Sydney Limited A method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1
EP2103943A1 (en) 2008-03-20 2009-09-23 F. Hoffman-la Roche AG GDF-15 for assessing a cardiovascular risk with respect to the administration of antiinflammatory drugs
JP2011523051A (ja) 2008-05-20 2011-08-04 エフ．ホフマン−ラ ロシュ アーゲー １型糖尿病におけるバイオマーカーとしてのｇｄｆ−１５
GB0902793D0 (en) * 2009-02-20 2009-04-08 Univ Gent GDF15 as molecular tool to monitor and enhance phenotypic stability of articular chondrocytes
US9212221B2 (en) * 2010-03-03 2015-12-15 Detroit R & D, Inc. Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
GB201004739D0 (en) 2010-03-22 2010-05-05 Prosidion Ltd Receptor modulators
MX355060B (es) * 2010-11-17 2018-04-03 Chugai Pharmaceutical Co Ltd Molecula multiespecifica de union a antigeno que tiene funcion alternativa a la funcion del factor viii de coagulacion sanguinea.
WO2012113103A1 (en) 2011-02-25 2012-08-30 Helsinn Healthcare S.A. Asymmetric ureas and medical uses thereof
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN105073133B (zh) 2012-12-21 2021-04-20 Aveo制药公司 抗gdf15抗体
JP6910800B2 (ja) 2014-06-20 2021-07-28 アベオ ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ１５調節剤を用いたうっ血性心不全及びその他の心機能不全の治療
EA201790051A1 (ru) 2014-06-20 2017-04-28 Авео Фармасьютикалз, Инк. Лечение хронического заболевания почек и другого нарушения функции почек при помощи модулятора gdf15

Also Published As

Publication number Publication date
MX370720B (es) 2019-12-20
WO2014100689A1 (en) 2014-06-26
US10597444B2 (en) 2020-03-24
HK1215670A1 (en) 2016-09-09
CA2896076C (en) 2022-12-06
JP2021061864A (ja) 2021-04-22
MX2015007751A (es) 2015-11-30
JP2016508984A (ja) 2016-03-24
DK2934584T3 (da) 2020-05-18
US20250277019A1 (en) 2025-09-04
CN105073133B (zh) 2021-04-20
EA201591198A1 (ru) 2015-11-30
US20160083465A1 (en) 2016-03-24
US20240166734A1 (en) 2024-05-23
AU2013364133A1 (en) 2015-07-16
US9725505B2 (en) 2017-08-08
EA038645B1 (ru) 2021-09-28
KR20150100837A (ko) 2015-09-02
EP3689370A1 (en) 2020-08-05
US20180142013A1 (en) 2018-05-24
US11725047B2 (en) 2023-08-15
US12258391B2 (en) 2025-03-25
CA2896076A1 (en) 2014-06-26
US9175076B2 (en) 2015-11-03
EP2934584B1 (en) 2020-02-19
BR112015014768A2 (pt) 2017-10-10
KR102208861B1 (ko) 2021-01-27
JP2019056018A (ja) 2019-04-11
US20140193427A1 (en) 2014-07-10
CN105073133A (zh) 2015-11-18
AR094271A1 (es) 2015-07-22
US20210101968A1 (en) 2021-04-08
AU2013364133B2 (en) 2018-10-11
ES2791183T3 (es) 2020-11-03
EP2934584A1 (en) 2015-10-28

Similar Documents

Publication Publication Date Title
JP6758832B2 (ja) 抗ｇｄｆ１５抗体
CN113286817B (zh) Dll3结合蛋白及使用方法
CN111050797B (zh) 抗tim-3抗体及其用途
JP2013529076A (ja) 抗ｆｇｆｒ２抗体
JP2022514693A (ja) Ｍｕｃ１８に特異的な抗体
AU2016204960A1 (en) 4-1BB binding molecules
TWI793395B (zh) 結合ｐｄ-ｌ１和ｏｘ４０的雙特異性抗體
JP2017518040A (ja) 新規の抗ｒｎｆ４３抗体および使用方法
JP2013533746A (ja) 抗ｒｏｎ抗体
TWI832013B (zh) 一種抗pd-l1抗原結合蛋白及其應用
AU2021305396A1 (en) Antibodies that bind PSMA and gamma-delta t cell receptors
AU2021221287A1 (en) Engineered anti-IL-2 antibodies
JP2022514786A (ja) Ｍｕｃ１８に特異的な抗体
JP2016516092A (ja) Ｍ−ｃｓｆを標的とする抗体
KR20240058149A (ko) Vista 항원-결합 분자를 사용한 암의 치료 및 예방
EP4393506A1 (en) Pharmaceutical composition of anti-il4r antibody and use thereof
HK40028061A (en) Anti-gdf15 antibodies
CN116783220A (zh) 抗bcma抗体及其制备方法和应用
HK1215670B (en) Anti-gdf15 antibodies
US20230064703A1 (en) Anti-gitr antibodies and uses thereof
TW202340254A (zh) 抗btla抗體及其於治療癌症之用途
CA3210910A1 (en) Anti-pd-l1 antibody and use thereof
CN120456923A (zh) 使用抗il-2抗体的方法
CN114929741A (zh) 针对lif的抗体及其用途
HK40017927A (en) Anti-tim-3 antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180524

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190121

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190311

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20190412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200525

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200902

R150 Certificate of patent or registration of utility model

Ref document number: 6758832

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250